Latest News:
July 20, 2010
Press Release: Fujirebio to acquire Innogenetics from Abbott
Fujirebio, a Miraca Holdings group company, announced today a definitive agreement with Abbott, the global healthcare company, to acquire all of the issued and outstanding shares of Innogenetics, a multi-national company that develops and markets a wide range of specialty diagnostics in the fields of infectious diseases, genetic testing, transplantation as well as neuro-degeneration.
May 4, 2009
BD and Fujirebio Diagnostics Sign Worldwide Agreement to Develop Biomarker Assays
to Improve Cancer Detection and Management
BD (Becton, Dickinson and Company; NYSE: BDX) and Fujirebio Diagnostics, Inc., announced today the signing of a worldwide development and supply agreement for oncology diagnostic assays.
December 10, 2009
Fujirebio Diagnostics Named Life Sciences Company of the Year
Eastern Technology Council Honors Malvern-based Company at Gala Awards Ceremony.
May 4, 2009
BD and Fujirebio Diagnostics Sign Worldwide Agreement to Develop Biomarker Assays
to Improve Cancer Detection and Management
BD (Becton, Dickinson and Company; NYSE: BDX) and Fujirebio Diagnostics, Inc., announced today the signing of a worldwide development and supply agreement for oncology diagnostic assays.
January 27, 2009
Fujirebio Diagnostics and Abbott Agree to Develop New Ovarian Cancer Test for Abbott's ARCHITECT® Analyzers
Fujirebio Diagnostics, Inc. and Abbott have signed a license agreement to develop a new ovarian cancer test for use on Abbott's automated ARCHITECT® diagnostic analyzers. Under the agreement, Fujirebio Diagnostics will develop and manufacture for Abbott the HE4 biomarker, a simple blood test that may help in the risk stratification of women at high risk for ovarian cancer, a difficult disease to detect in its early stage.
January 26, 2009
Pivotal Data Published for First Biomarker Combination Test to Determine Risk of Ovarian Cancer in Women Who Present With Pelvic Mass
A pivotal clinical trial published in the January 2009 issue of the journal Gynecologic Oncology demonstrated the utility of combining Fujirebio Diagnostics' HE4 and the CA125 test as an aid in estimating the risk of epithelial ovarian cancer in premenopausal or postmenopausal women presenting with pelvic mass. The HE4 test, which is under review by the U.S. Food and Drug Administration (FDA), was reported to successfully stratify patients into high- and low-risk groups when combined with CA125.
Upcoming Events:
January 28-31, 2010
GOG 80th Semi-Annual Meeting, San Diego, CA
http://www.gog.org/meetinginformation.html
January 29-30, 2010
7th European Congress: Perspectives in Gynecologic Oncology; Barcelona, Spain
http://www.imedex.com/appweb/announcements/a132-01.asp
March 14-17, 2010
SGO Annual Meeting, San Francisco, CA, Booth#104
http://www.sgo.org/content.aspx?id=58
April 15-16, 2010
NSGO – Nordic Society of Gynecologic Oncology, Copenhagen, Denmark
http://www.nsgo.org/nsgo_meeting_20101